A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 334 participants.

Also called NCT02988973

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 334 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02988973
Other papers using this trial's data
  • Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients American journal of nephrology, 2021 DOI, PubMed 34628408, PMC8686708 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02988973. Randomized; no masking; primary purpose treatment. Start 2017-01-12 (actual); primary completion 2019-09-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Intervention (Drug)
roxadustat
Intervention (Drug)
DA
Lead sponsor
Astellas Pharma Inc (class: industry)
Collaborator
Kyntra Bio (class: industry)

Record details

Record id
cardio:ct-nct02988973
Content hash
735f479f2b46d4c97880efa5f2987cb7ceed0795cf9fbce365c300a864666c11